Larimar Therapeutics IncNASDAQ:LRMR
- LAST PRICE6.6450
- TODAY'S CHANGE (%)0.3550 (5.6439%)
- Bid / Lots6.6200/ 20
- Ask / Lots6.6700/ 6
- Open / Previous Close6.3900 / 6.2900
- Day Range
- 52 Week Range
- Volume892,533
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LRMR |
|---|---|---|
| 09:32 ET | 4977 | 6.345 |
| 09:34 ET | 600 | 6.3119 |
| 09:36 ET | 7700 | 6.32 |
| 09:38 ET | 10381 | 6.44 |
| 09:39 ET | 4750 | 6.445 |
| 09:41 ET | 4678 | 6.4665 |
| 09:43 ET | 81299 | 6.505 |
| 09:45 ET | 2962 | 6.6 |
| 09:48 ET | 39418 | 6.63 |
| 09:50 ET | 6246 | 6.64 |
| 09:52 ET | 3697 | 6.59 |
| 09:54 ET | 13772 | 6.63 |
| 09:56 ET | 15088 | 6.74 |
| 09:57 ET | 10022 | 6.7566 |
| 09:59 ET | 2150 | 6.71 |
| 10:01 ET | 3435 | 6.73 |
| 10:03 ET | 6556 | 6.7483 |
| 10:06 ET | 10692 | 6.795 |
| 10:08 ET | 12161 | 6.91 |
| 10:10 ET | 20384 | 6.9297 |
| 10:12 ET | 7538 | 6.955 |
| 10:14 ET | 19797 | 7.03 |
| 10:15 ET | 10934 | 6.97 |
| 10:17 ET | 4311 | 7.015 |
| 10:19 ET | 6232 | 7.025 |
| 10:21 ET | 6516 | 7.02 |
| 10:24 ET | 3053 | 6.97 |
| 10:26 ET | 16984 | 7.065 |
| 10:28 ET | 16794 | 7.13 |
| 10:30 ET | 13831 | 7.1 |
| 10:32 ET | 36376 | 7.165 |
| 10:33 ET | 13725 | 7.2 |
| 10:35 ET | 12576 | 7.2 |
| 10:37 ET | 104888 | 7.25 |
| 10:39 ET | 27268 | 7.0601 |
| 10:42 ET | 13507 | 6.98 |
| 10:44 ET | 2198 | 6.985 |
| 10:46 ET | 2995 | 7.01 |
| 10:48 ET | 3287 | 7.04 |
| 10:50 ET | 5697 | 6.99 |
| 10:51 ET | 816 | 6.98 |
| 10:53 ET | 5369 | 6.985 |
| 10:55 ET | 34662 | 6.8 |
| 10:57 ET | 24328 | 6.68 |
| 11:00 ET | 3172 | 6.7 |
| 11:02 ET | 7503 | 6.65 |
| 11:04 ET | 14021 | 6.56 |
| 11:06 ET | 956 | 6.54 |
| 11:08 ET | 225 | 6.52 |
| 11:09 ET | 1246 | 6.55 |
| 11:11 ET | 95212 | 6.5 |
| 11:13 ET | 800 | 6.49 |
| 11:15 ET | 1014 | 6.5024 |
| 11:18 ET | 1450 | 6.475 |
| 11:20 ET | 1801 | 6.48 |
| 11:22 ET | 9159 | 6.51 |
| 11:24 ET | 3965 | 6.6018 |
| 11:26 ET | 2905 | 6.6576 |
| 11:27 ET | 4340 | 6.645 |
Today
DJ Larimar Therapeutics Initiated at Outperform by Wedbush, from 1 hour ago by Dow Jones
1 hour ago by Dow Jones
Yesterday
DJ Larimar Therapeutics Initiated at Buy by HC Wainwright & Co., from 6:22AM ET on Wednesday Oct 02, 2024 by Dow Jones
6:22AM ET on Wednesday Oct 02, 2024 by Dow Jones
Sep 19, 2024
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research, from 7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
7:00AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 12, 2024
DJ Larimar Therapeutics Initiated at Buy by Jones Trading, from 8:16AM ET on Thursday Sep 12, 2024 by Dow Jones
8:16AM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 4, 2024
DJ Larimar Therapeutics Initiated at Outperform by Baird, from 5:53AM ET on Wednesday Sep 04, 2024 by Dow Jones
5:53AM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Larimar Therapeutics Inc | 401.3M | -6.0x | --- |
Prime Medicine Inc | 411.7M | -1.6x | --- |
Compass Pathways PLC | 385.7M | -2.5x | --- |
Northwest Biotherapeutics Inc | 395.8M | -4.8x | --- |
Instil Bio Inc | 377.2M | -3.1x | --- |
Aura Biosciences Inc | 433.6M | -4.9x | --- |
Company Information
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Contact Information
- Headquarters
- THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
- Phone
- 617-622-4003
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Truitt
- President, Chief Executive Officer, Director
- Carole Ben-Maimon
- Chief Financial Officer, Secretary
- Michael Celano
- Chief Medical Officer
- Russell Clayton
- Chief Development Officer
- Gopi Shankar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $401.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 63.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-1.11 |
Book Value | $1.86 |
P/E Ratio | -6.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
